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Background/Aims: Inhibition of tumor necrosis factor (TNF) is an effective 
treatment for rheumatoid arthritis (RA), but safety concerns about malignancy 
remain. The aim of this study was to evaluate cancer risk in RA patients treat-
ed with TNF inhibitors (TNFi), based on Korean Nationwide Health Insurance 
claims data. 
Methods: Patients with seropositive RA were selected from the health insurance 
database containing all citizens’ medical information, based on both RA diag-
nosis codes and medications. Between 2010 and 2014, RA patients treated with 
conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and 
TNFi were enrolled and followed up. We compared the cancer incidence between 
patients treated with TNFi and csDMARDs using incidence rate ratios (IRRs) af-
ter adjustment for age, gender, and observational periods.
Results: Of 45,423 selected patients with seropositive RA, 2,337 were treated with 
TNFi and 43,086 were treated with csDMARDs. The TNFi group was younger and 
was followed-up for a longer duration. During the observational period, 1,732 and 
49 cases of cancer were detected in patients treated with csDMARDs and TNFi, 
respectively. Old age and male sex were associated with cancer occurrence. Ad-
justed IRRs for all cancers and common cancers demonstrated that cancer inci-
dence did not differ significantly between the TNFi group and csDMARDs group 
(IRR = 0.913 for all cancers, p = 0.546). 
Conclusions: This study revealed that cancer incidence was similar in RA patients 
treated with TNFi and csDMARDs. Anti-TNF therapy may be a safe therapeutic 
option for RA treatment, in terms of malignancy.
Keywords: Rheumatoid arthritis; Tumor necrosis factor; TNF inhibitors; Malig-
nancy; Cancer
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INTRODUCTION
Rheumatoid arthritis (RA) is a systemic autoimmune 
disease requiring treatment with immunosuppressive 
agents. Proper management of RA includes the use of 
disease-modifying anti-rheumatic drugs (DMARDs) 
to control systemic and local inflammation [1,2]. Re-
cently, development of biological DMARDs, including 
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tumor necrosis factor inhibitors (TNFi), has enabled 
more effective disease activity control. Because of the 
proinflammatory role of TNF, treatment with TNFi has 
proven to be beneficial for RA patients with inadequate 
responses to conventional synthetic DMARDs (csD-
MARDs) [3]. However, anti-TNF therapy has also raised 
safety concerns, because relative immune deficiency fol-
lowing TNF inhibition can increase the risk of infection 
and malignancy. Since TNF plays an important role in 
cancer pathogenesis, the risk for cancer during and after 
anti-TNF therapy has emerged as a major concern [4,5]. 
TNF was primarily identified as an anti-tumor factor 
in the serum of Bacillus Calmette-Guérin-infected mice 
treated with endotoxin [6,7]. Serum transfer from these 
mice to other mice with subcutaneously transplanted 
sarcomas reduced the size of tumors. Several subse-
quent studies also indicated that systemic administra-
tion of TNF could suppress tumor progression, whereas 
other studies revealed that downregulation of TNF para-
doxically reduced tumor formation and metastasis [4]. 
Like these preclinical studies, clinical trials were also 
inconclusive, with conflicting results regarding TNF 
effects on carcinogenesis. Both treatment with recom-
binant TNF and TNFi were found to be therapeutically 
ineffective in cancer patients [4,5]. 
Since TNFi has become available and widely used in 
RA patients, the risk for malignancy in patients treat-
ed with TNFi has been constantly studied. Earlier data 
from clinical trials indicated that the risk for malig-
nancy was greater in RA patients treated with TNFi than 
in TNFi-naïve patients [8]. However, these studies were 
limited by small sample sizes and heterogeneous study 
populations. The majority of subsequent studies based 
on a large national registry suggested that overall can-
cer incidence did not increase during or after anti-TNF 
therapy [9-12]. 
Despite substantial previous research, efforts to elu-
cidate the association between anti-TNF therapy and 
cancer are still ongoing. Because cancer incidence is in-
fluenced by genetic predisposition and environmental 
factors, cancer epidemiology differs between continents 
and countries [13]. Thus, it is desirable to estimate can-
cer incidence from a nationwide database. In South Ko-
rea, the national healthcare system provides insurance 
coverage for nearly all citizens. All hospitals and medical 
institutions submit insurance claims to the Health In-
surance Review and Assessment Service (HIRA), which 
reviews all insurance claims and makes decisions re-
garding payment [14]. Because the submitted data in-
clude information about diagnosis and treatment for all 
citizens, the HIRA database can be used to obtain na-
tionwide medical information.
In this study, we used the HIRA database to evalu-
ate malignancy risk in RA patients following anti-TNF 
therapy. The incidence of all cancers and common can-
cers were compared in RA patients treated with TNFi or 
csDMARDs.
METHODS
Identification of RA patients
We retrieved data about RA patients from the HIRA da-
tabase using both the diagnosis code from the Interna-
tional Classification of Disease, Revision 10 (ICD10) and 
patient medications, between January, 2010 and Decem-
ber, 2013. As previously reported, identification of RA 
patient is a critical step in studies conducted with the 
health insurance claims database [15,16]. The RA (M05) 
diagnostic code was primarily used to select the study 
population. We reviewed the lists of medications in pa-
tients with M05 codes to increase diagnostic reliability. 
Patients with RA codes were confirmed as RA patients 
if they had a prescription for TNFi, methotrexate, le-
flunomide, or more than one other csDMARD besides 
methotrexate or leflunomide (Fig. 1). TNFi included 
infliximab, etanercept, adalimumab, and golimumab. 
Because RA treatment with certolizumab was not cov-
ered by the National Health Insurance System during 
the study period, prescriptions for certolizumab were 
negligible. Other csDMARDs included hydroxychloro-
quine, sulfasalazine, cyclosporine, tacrolimus, azathi-
oprine, mizoribine, and bucillamine. Although M06 
codes possibly include seronegative RA, combination of 
M06 codes and medication review still showed low di-
agnostic reliability. Thus, patients with M06 codes were 
excluded from the analysis. 
All identified patients with RA were classified accord-
ing to their medications. The TNFi group was defined 
as patients who were prescribed with TNFi more than 
once. TNFi-naïve patients treated only with csDMARDs 
were categorized into the csDMARDs group. In the in-
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surance claims database, patient names and national 
registration numbers were deleted to ensure the patient 
confidentiality. This study was approved by the HIRA 
Research Ethics Committee.
Malignancy definition
Malignancy occurrence was defined as the new appear-
ance of a cancer-related ICD10 code (C00-D09) in the 
insurance claims during the study period. In these cas-
es, previous records were reviewed to find out the past 
history of malignancy. If there was no reported cancer 
for more than 1  year prior to record acquisition, we de-
fined that cancer as newly developed. Patients with co-
morbid cancer at the entry point were excluded. Since 
patients with cancer-related ICD10 codes were entered 
into a co-payment program based on the clinicopatho-
logic evaluation, the diagnosis of cancer was quite reli-
able.
Follow-up duration was determined by the interval 
between entry into and exit from this study for each pa-
tient (Fig. 2). The entry point for patients treated with 
csDMARDs was RA identification. When RA codes were 
initially introduced within the study period, patients 
were enrolled at the time of RA diagnosis. For patients 
with new RA onset, insurance claims from the year be-
fore entry were reviewed to rule out a prior RA diagno-
sis. If RA codes were found before the study period, the 
entry point was defined as initiation of the study period. 
In patients treated with TNFi, the entry point was deter-
mined by TNFi treatment initiation. If a patient began 
TNFi treatment before 2010, the patient was traced from 
the study beginning. Follow-up was terminated in cases 
of malignancy. If a malignancy was not found, patients 
were traced until the end of the study. 
Statistical analysis
Demographic data such as age and gender were com-
pared with Student t test and chi-square tests, respec-
tively. Differences in time to cancer diagnosis between 
Figure 1. Selection of rheumatoid arthritis (RA) patient from 
the Health Insurance Review and Assessment Service (HIRA) 
database. Patients were classified as having RA according 
to their diagnosis codes and medications. If patients with 
RA codes (M05) were prescribed with tumor necrosis fac-
tor inhibitors (TNFi), methotrexate, lef lunomide, or more 
than one conventional synthetic disease-modifying anti-
rheumatic drugs (csDMARDs), they were classif ied as RA 
patients. Other csDMARDs except methotrexate, and leflu-
nomide included hydroxychloroquine, sulfasalazine, cyclo-
sporine, tacrolimus, azathioprine, mizoribine, and bucilla-
mine.
RA codes (M05) +
TNFi
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Figure 2. Schematic diagram showing the study design. 
(A) Patients treated with conventional synthetic disease-
modifying anti-rheumatic drugs (csDMARDs) were enrolled 
at study initiation or rheumatoid arthritis (RA) diagnosis. 
Patients were traced until cancer occurrence or study ter-
mination. (B) Patients treated with tumor necrosis factor 
inhibitors (TNFi) were enrolled at introduction of anti-TNF 
therapy or study initiation. Follow-up was terminated when 
cancer was newly detected or the study period ended. R, 
diagnosis of RA; C, diagnosis of cancer; T, introduction of 
TNFi.
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patients treated with TNFi and csDMARDs were ana-
lyzed with the Wilcoxon rank-sum test.
Cancer incidence was presented as events/100,000 
person-years for the entire study population. The inci-
dence rate ratio (IRR) was estimated with a Cox regres-
sion model, adjusted for age, gender, and follow-up du-
ration. We compared the incidence for all cancers and 
site-specific cancers between the TNFi and csDMARDs 
groups with IRR. A p < 0.05 was considered significant. 
All statistical analyses were performed with SAS 9.1 soft-
ware (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient characteristics
We retrieved 45,423 patients with seropositive RA from 
the HIRA database, based on the algorithm for patient 
selection (Fig. 1). Of the selected patients, 2,337 were 
treated with TNFi. Patient characteristics at study en-
rollment are presented in Table 1. The mean age of RA 
patients was 57.49 years, and 79.7% of patients were fe-
male. The TNFi group was younger than the csDMARDs 
group, but the sex ratios were similar between the two 
groups. More patients in the TNFi group were enrolled 
in 2010, and thus follow-up duration was longer for the 
TNFi group (3.49 years vs. 3.19 years for the csCMARDs 
group; p < 0.001). The most frequently used drug in the 
TNFi group was etanercept (40.95%), followed by adali-
mumab (39.97%), infliximab (17.93%), and golimumab 
(1.16%). 
Characteristics of RA patients with cancer 
Among 45,423 patients, 1,781 cancer cases were newly de-
tected. Cancer diagnosis was more frequent in elderly 
patients, and the proportion of male patients was high-
er in cancer group. Distribution of TNFi did not differ 
significantly between patients with and without cancer 
(Table 2).
During the observational period, 1,732 patients (4.02%) 
in the csDMARDs group and 49 patients (2.10%) in the 
TNFi group were diagnosed with cancer (Table 3). The 
crude incidence rates for cancer were 1,257/100,000 pa-
tient-years and 600/100,000 patient-years in patients 
treated with csDMARDs and TNFi, respectively. The 
median interval between enrollment and cancer diag-
nosis was 20.06 months for the entire study population, 
and the time to cancer diagnosis was comparable in pa-
Table 1. Baseline characteristics for Korean patients with rheumatoid arthritis 
Characteristic All patient (n = 45,423)
Patient treated with csDMARD 
(n = 43,086)
Patient treated with TNFi 
(n = 2,337)
p value
Age, yr 57.49 ± 13.25 57.70 ± 13.17 53.63 ± 14.04 < 0.001
Female sex 36,212 (79.72) 34,382 (79.80) 1,830 (78.31) 0.080
Use of MTX 33,366 (73.46) 31,359 (72.78) 2,007 (85.88) < 0.001
Calendar year of enrollment < 0.001
2010 33,432 (73.60) 31,546 (73.22) 1,886 (80.70)
2011 3,728 (8.21) 3,543 (8.22) 185 (7.92)
2012 3,959 (8.72) 3,805 (8.83) 154 (6.59)
2013 4,304 (9.48) 4,192 (9.73) 112 (4.79)
Duration of follow-up, yr 3.21 ± 1.23 3.19 ± 1.24 3.49 ± 0.99 < 0.001
Distribution of TNFi
Etanercept - - 957 (40.95)
Infliximab - - 419 (17.93)
Adalimumab - - 934 (39.97)
Golimumab - - 27 (1.16)
Values are presented as mean ± SD or number (%).
csDMARD, conventional synthetic disease-modifying anti-rheumatic drug; TNFi, tumor necrosis factor inhibitors; MTX, 
methotrexate.
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tients with and without anti-TNF therapy (p = 0.471). 
Cancer incidence 
Incidence rates for all cancers and common cancers are 
presented in Table 4. The most common cancer was 
thyroid cancer, followed by lung cancer, gastric cancer, 
colon cancer, breast cancer, and liver cancer in descend-
ing order. Lymphoma, a common cancer in RA patients, 
was not detected in patients treated with TNFi. 
The overall cancer incidence was higher in the csD-
MARDs group than in the TNFi group. However, when 
the IRRs were adjusted for age, gender, and observation-
al period, there was no difference in cancer incidence 
for any kind between patients treated with csDMARDs 
and those treated with TNFi.
DISCUSSION
This study demonstrated that malignancy incidence was 
similar in seropositive RA patients treated with TNFi 
and those treated with csDMARDs. The IRRs adjusted 
for age, gender, and observational period revealed that 
the incidence for all cancers and site-specific cancers 
did not differ significantly between the groups. 
To our knowledge, this is the first study comprising 
all citizens to investigate the cancer incidence in RA 
subsequent to anti-TNF therapy. A single study con-
ducted in Taiwan included all citizens treated with 
TNFi [12]. The Taiwanese study also used their National 
Health Insurance Database, and selected matched con-
trols from patients treated with csDMARDs. We were 
able to minimize the drop-out that affects the detection 
Table 2. Comparison between rheumatoid arthritis patients with and without cancer 
Variable Patient without cancer (n = 43,642) Patient with cancer (n = 1,781) p value
Age, yr 57.23 ± 13.23 63.71 ± 12.07 < 0.001
Male sex 8,695 (19.92) 516 (28.97) < 0.001
Distribution of TNFi 0.268
Etanercept 941 (41.13) 16 (32.65)
Infliximab 412 (18.01) 7 (14.29)
Adalimumab 908 (39.69) 26 (53.06)
Golimumab 27 (1.18) 0
Values are presented as mean ± SD or number (%).
TNFi, tumor necrosis factor inhibitors.
Table 3. Cancer detection in patients treated with csDMARDs and TNFi during the study period
Variable All patient (n = 45,423)
Patient treated with csDMARD 
(n = 43,086)
Patient treated with TNFi 
(n = 2,337)
p value
Patient-years 145,944 137,746 8,037 < 0.001
Cancer case 1,781 (3.92) 1,732 (4.02) 49 (2.10) < 0.001
Events/100,000 patient-years 1,220.33 1,257.39 600.26 < 0.001
Cancer diagnosis calendar 
 year, n (% within all cancer)
0.038
2010 378 (21.22) 372 (21.48) 6 (12.24)
2011 465 (26.11) 456 (26.33) 9 (18.37)
2012 472 (26.50) 459 (26.50) 13 (26.53)
2013 466 (26.17) 445 (25.69) 21 (42.86)
Time to cancer, mon 20.06 (8.56–31.56) 20.21 (8.66–31.77) 18.60 (7.58–29.62) 0.471
Values are presented as number (%) or median (interquartile range).
csDMARD, conventional synthetic disease-modifying anti-rheumatic drug; TNFi, tumor necrosis factor inhibitors.
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of cancer occurrence by using the HIRA database, be-
cause all citizens were registered in the HIRA database. 
Inclusion of all citizens requires proper selection of 
study population. Previously, Cho et al. [16] suggested 
that selecting patients according to diagnosis codes and 
prescribed drugs from the HIRA database was a reliable 
way to identify patients with RA. However, we could in-
clude only patients with seropositive RA, because of the 
reliability of diagnosis codes. 
Previous studies have reported a wide range of can-
cer incidence rates, between 3.8 and 9.3 per 1,000 pa-
tient-years [10-12,17,18]. Estimation of cancer risk can 
vary due to ethnic diversity and environmental con-
tributions [13]. Excluding thyroid cancer, the crude 
cancer incidence in Korean RA patient was 8.2/1,000 
patient-years. Because we included the diagnosis of car-
cinoma in situ, the estimated incidence would be rel-
atively higher compared to the previous research. In a 
prior study conducted in Korea between 2001 and 2007, 
the overall cancer incidence in RA patients was 4.6/1,000 
patient-years [19]. This cancer occurrence could have 
been underestimated, because enrollment and fol-
low-up for RA patients was limited to a single center. 
Nonetheless, the incidence was much lower than that 
identified in this study. This discrepancy may be due to 
differences in patient characteristics and study periods. 
The present study included a higher proportion of older 
and male patients, who develop cancers more frequent-
ly, according to the National Cancer Information Center 
[20]. Moreover, cancer incidence has increased contin-
uously in the general population since 2000, and the 
same trend should be expected in RA patients. 
Previously, clinical studies investigating the associa-
tion between anti-TNF therapy and cancer have shown 
inconsistent results. An initial-stage meta-analysis of 
clinical trials revealed increased cancer incidence in 
patients treated with adalimumab and infliximab [8]. 
However, the observational period, ranging from 3 
months to 1 year, was too short to evaluate the carcino-
genic effects of TNFi. Subsequent observational studies 
with larger sample sizes and longer durations revealed 
similar cancer incidences, although there were contro-
versies regarding several kinds of cancers [21]. Recently, 
a Taiwanese nationwide cohort study demonstrated that 
cancer risk was lower in patients treated with anti-TNF 
therapy [12]. The overall cancer incidence excluding 
hematologic malignancy and standardized incidence 
ratios for lung, breast, and genitourinary cancers were 
significantly lower in the biologics cohort [12]. Our study 
also indicated that crude cancer incidence was lower in 
patients treated with TNFi than in those treated with 
csDMARDs. However, there were significant differences 
between the groups in clinical characteristics affecting 
cancer incidence, such as age, gender, and follow-up 
duration. When the IRRs were adjusted for age, gender, 
and observational period, incidence rates for all cancers 
Table 4. Cancer incidence in rheumatoid arthritis patients treated with csDMARDs and TNFi 
Variable
Total (n = 45,423) csDMARD (n = 43,086) TNFi (n = 2,339) IRR (95% CI)a
p value
Case Incidenceb Case Incidenceb Case Incidenceb TNFi vs. csDMARDs
All cancer 1,781 1,220.33 1,732 1,257.39 49 599.57 0.913 (0.679–1.227) 0.546
Thyroid cancer 312 404.52 302 415.98 10 205.94 0.966 (0.510–1.830) 0.916
Lung cancer 239 299.13 232 306.81 7 156.44 1.038 (0.484–2.227) 0.923
Gastric cancer 194 249.33 188 254.57 6 151.25 1.146 (0.503–2.610) 0.745
Colon cancer 180 234.90 177 243.80 3 70.24 0.623 (0.198–1.965) 0.419
Breast cancer (in female) 147 199.52 142 202.44 5 146.92 1.184 (0.480–2.919) 0.714
Prostate cancer (in male) 81 158.09 80 119.25 1 13.54 0.445 (0.061–3.246) 0.425
Liver cancer 99 132.33 98 138.52 1 20.20 0.339 (0.047–2.445) 0.283
Lymphoma 67 76.39 67 80.53 0 0.00 - -
csDMARD, conventional synthetic disease-modifying anti-rheumatic drug; TNFi, tumor necrosis factor inhibitors; IRR, inci-
dence rate ratio; CI, confidence interval.
aAdjusted for age, gender, and observational period.
bDefined as ‘cancer cases/100,000 patient-years.’
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and site-specific cancers were comparable in patients 
treated with csDMARDs and TNFi. 
The pathogenesis of cancer is closely linked to inflam-
mation and immunity [22]. In general, chronic inflam-
mation triggered by infection or autoimmunity can be 
a risk factor for cancer occurrence. In RA patients, long-
standing disease and high disease activity were found 
to increase cancer risk, probably through chronic in-
flammatory response [23,24]. Thus, the effective control 
of inflammation by TNFi might reduce the cancer risk, 
although the effects of TNF on carcinogenesis are con-
troversial [5]. However, to elucidate causal links between 
anti-TNF therapy and cancer, further research will be 
required. 
The most common cancer in all patients with RA was 
thyroid cancer, followed by lung cancer, stomach can-
cer, and colon cancer in descending order. The high in-
cidence of thyroid cancer is in line with its incidence 
in the general population during the study period, due 
to increased medical surveillance [25]. Except thyroid 
cancer, the most common site of cancer was lung in RA 
patients, whereas stomach cancer was most common in 
the general population during the study period. An in-
creased risk for lung cancer in RA patients has been sug-
gested by many previous studies [26]. In this study, lym-
phoma was not detected among TNFi-treated patients. 
The present study has several limitations. First of all, 
it was difficult to analyze the effects of other confound-
ing variables, such as comorbidities, medications, and 
disease activity and duration. Information about comor-
bidities and medications was insufficient for further 
analysis due to the limitations of the database. More-
over, disease-specific features were not accessible, be-
cause of personal information protection. However, we 
assumed that the csDMARDs group also had active RA 
requiring methotrexate, leflunomide, or combination of 
csDMARDs. Second, patients with seronegative RA were 
not included in the analysis. Third, the study period was 
4 years, and the mean follow-up duration was 3.2 years, 
which is a relatively short period for evaluating TNFi 
effects on carcinogenesis. Finally, we did not compare 
cancer incidence between RA patients and the general 
population, due to limited HIRA database information 
and cancer statistics. 
This study showed the nationwide cancer incidence 
in Korean patients with RA and evaluated the associa-
tion between anti-TNF therapy and cancer risk, using 
the database of all citizens. However, we should be aware 
that this study provides only rudimentary informa-
tion, which requires further evaluation using well-de-
signed registry or cohort. Recently, the Korean College 
of Rheumatology has constructed a national biologics 
registry for safety evaluation in treatment with biolog-
ics [27]. Forthcoming data from this nationwide registry 
will provide a better understanding of the association 
between biologic therapies and cancer. 
In conclusion, the risk of malignancy did not differ 
significantly between RA patients treated with TNFi and 
those treated with csDMARDs based on the insurance 
claim data. In terms of malignancy, anti-TNF therapy 
may be an effective therapeutic option with an accept-
able safety profile for patients with inadequate respons-
es to csDMARDs. This will be illuminated more thor-
oughly in a prospective observational registry set up.
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KEY MESSAGE 
1. We used the data from National Health Insur-
ance claims database to determine the risk of 
cancer in patients with rheumatoid arthritis 
(RA). 
2. The risk of malignancy did not differ signifi-
cantly between patients treated with tumor ne-
crosis factor (TNF) inhibitors and conventional 
synthetic disease modifying anti-rheumatic 
drugs. 
3. Anti-TNF therapy would be a safe therapeutic 
option for active RA, in terms of malignancy.
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